TG Therapeutics, Inc. (NASDAQ:TGTX) enjoyed a 159.76% run-up in share price since hitting record low of $4.10. The stock managed 15.76% rise and now stands at $10.65 as of 01/11/2018. At recent session, the prices were hovering between $9.25 and $10.8. This company shares are 158.97% off its target price of $27.58 and the current market capitalization stands at $731.76M. The recent change has given its price a 29.05% lead over SMA 50 and -30.62% deficit over its 52-week high. The stock witnessed 29.09% gains, -8.19% declines and -0.47% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TGTX’s volatility during a week at 8.13% and during a month it has been found around 5.76%.TG Therapeutics, Inc. (TGTX) Top Holders
Institutional investors currently hold around $328 million or 57.8% in TGTX stock. Look at its top three institutional owners. Fmr Llc owns $59.36 million in TG Therapeutics, Inc., which represents roughly 8.11% of the company’s market cap and approximately 18.1% of the institutional ownership. Similar statistics are true for the second largest owner, Bridger Management, Llc, which owns 5,295,044 shares of the stock are valued at $48.71 million. The third largest holder is Blackrock Inc., which currently holds $30.36 million worth of this stock and that ownership represents nearly 4.15% of its market capitalization.TG Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 39 institutional holders increased their position in TG Therapeutics, Inc. (NASDAQ:TGTX) by some 2,544,588 shares, 38 decreased positions by 1,300,811 and 32 held positions by 31,772,268. That puts total institutional holdings at 35,617,667 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 39,823 shares while 10 institutional investors sold out their entire positions totaling 431,053 shares.TG Therapeutics, Inc. (NASDAQ:TGTX) Insider Trades
Multiple company employees have indulged in significant insider trading. TG Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO, Secretary and Treasurer Power Sean A has sold 32,006 shares of TG Therapeutics, Inc. (TGTX) in trading session dated Jan. 02, 2018. These shares are worth $272,051 and were traded at $8.5 each. The SEC filing shows that Power Sean A performed a sale of 59,976 shares. The CFO, Secretary and Treasurer disposed these shares by way of transaction on Jun. 19, 2017. The company’s shares were given away at $11.09 per share worth to an income of some $665,134 on account of Power Sean A.
Director, Kennedy William James, sold 8,548 common shares of TG Therapeutics, Inc. (TGTX) in the open market. In a transaction dated Apr. 11, 2017, the shares were put up for sale at an average price of $10.27, raking in a sum of $87,788. After this sale, 70,401 common shares of TGTX are directly owned by the insider, with total stake valued at $749,771.
In the transaction dated Apr. 04, 2017, the great number of shares disposed came courtesy the Director; Charney Laurence N disposed a total of 7,000 shares at an average price of $11.17, amounting to approximately $78,190. The insider now directly owns 88,949 shares worth $947,307.TG Therapeutics, Inc. (TGTX) Analyst Guide
Several analysts have released their opinion on TG Therapeutics, Inc. (NASDAQ:TGTX), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.